# EVAX catalysts: Evaxion A/S PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/evax/catalysts

> Evaxion A/S (EVAX) has no upcoming catalysts in this calendar. The latest recorded is the EVX-01 primary completion, April 7, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for EVAX?

Evaxion A/S (EVAX) has no upcoming catalysts in this calendar. The latest recorded is the EVX-01 primary completion, April 7, 2026. ClinicalTrials.gov: "NCT05309421 (A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-07 (ACTUAL); Lead Sponsor Evaxion Biotech A/S." [Calendar and source filings](https://sec-api.dev/companies/evax/catalysts)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05309421 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/companies/evax/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Evaxion A/S |
| Ticker | EVAX (Nasdaq) |
| SEC CIK | 1828253 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/evax |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Nov 2022 | [Neopeptides NDA/BLA submission](https://sec-api.dev/pdufa/neopeptides) | EVAX | with metastatic melanoma | completed | "In November 2022, we submitted an Investigational New Drug Application, or IND, along with a Fast Track designation request to the U.S. Food and Drug Administration, or FDA, for the Phase 2 clinical trial of EVX-01 in combination with KEYTRUDA® for the treatment of patients with metastatic melanoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/evax20241231_20f.htm)) |
| November 23, 2022 | [Evaxion A/S FDA approval](https://sec-api.dev/companies/evax/catalysts) | EVAX |  | completed, approved | "Further, on November 23, 2022, we submitted an IND to the FDA, which was granted approval on December 22, 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1828253/000117184325001916/evax20241231_20f.htm)) |
| May 22, 2025 | [Neopeptides trial start](https://sec-api.dev/pdufa/neopeptides) | EVAX |  | completed | "COPENHAGEN, Denmark, May 22, 2025 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset EVX-01." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828253/000117184325003392/exh_991.htm)) |
| 2H 2025 | [Neopeptides topline data readout](https://sec-api.dev/pdufa/neopeptides) | EVAX |  | scheduled | "Continued progression of the development of our lead asset EVX-01 with the ongoing phase 2 trial on track for two-year readout in the second half of 2025, and the first patient in the one-year trial extension being dosed in May." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828253/000117184325003452/exh_991.htm)) |
| 2H 2025 | [Neopeptides interim data readout](https://sec-api.dev/pdufa/neopeptides) | EVAX |  | scheduled | "The continued progression of the phase 2 trial with our lead asset, personalized cancer vaccine EVX-01, demonstrating convincing one-year interim data and on track for two-year clinical efficacy readout in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828253/000117184325001904/exh_991.htm)) |
| April 7, 2026 | [EVX-01 primary completion](https://sec-api.dev/pdufa/evx-01) | EVAX | Melanoma Stage IV; Unresectable Melanoma | completed | "NCT05309421 (A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-07 (ACTUAL); Lead Sponsor Evaxion Biotech A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05309421)) |

## Drugs

- [EVX-01](https://sec-api.dev/pdufa/evx-01): Melanoma Stage IV
- [Neopeptides](https://sec-api.dev/pdufa/neopeptides): with metastatic melanoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/evax/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EVAX catalysts: Evaxion A/S PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/evax/catalysts

```bibtex
@misc{secapidev_companies_evax_catalysts_20261116,
  title        = {EVAX catalysts: Evaxion A/S PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/evax/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_evax_catalysts_20261116","title":"EVAX catalysts: Evaxion A/S PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/evax/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
